Results 291 to 300 of about 406,045 (339)

Supplementary Figure S8 from Extracellular Matrix–MYCAF Signatures Correlate with Resistance to Neoadjuvant aPD-L1 Immune Checkpoint Inhibition with Durvalumab + Metformin in HPV+ HNSCC

Pablo Llerena, Hani Samarah, Kathryn Nunes, Zhao Lin, Kelly Bridgham, Sruti Tekumalla, Amiti Jain, Larry A. Harshyne, Sanket K. Shukla, Ioannis Vathiotis, Madalina Tuluc, Stacey Gargano, John R. Eisenbrey, Scott W. Keith, David M. Cognetti, Voichita Bar‐Ad, Adam Luginbuhl, Rita Axelrod, Rajanikanth Vadigepalli, Hushan Yang, Diana Whitaker‐Menezes, Megan Roche, Mỹ G. Mahoney, Athanassios Argiris, Charalambos Solomides, Jennifer M. Johnson, Mouadh Barbirou, Amanda Miller, Andrew P. South, Ramkrishna Mitra, Alban J. Linnenbach, Ubaldo Martinez‐Outschoorn, Joseph Curry   +32 more
openalex   +1 more source

Immune Checkpoint Therapy for Thymic Carcinoma. [PDF]

Cancers (Basel)
Li J, Mao F, Liu H, Chen J.
europepmc   +1 more source

CD24 as an innate immune checkpoint in solid tumors: biology, biomarker stratification, and therapeutic translation. [PDF]

Front Immunol
Zhou W, Huang X, Jia G, Lu C, Ma W.
europepmc   +1 more source

Clinical Characteristics and Risk Factors of Immune Checkpoint Inhibitor-Related Myocarditis: A Real World Observational Study. [PDF]

Clin Cardiol
Zhan M, Long Q, Liu R, Huang L, Wu B, Xu T, He J.   +6 more
europepmc   +1 more source

Artificial Intelligence-Enabled Multi-Omics for Predicting Immune Checkpoint Inhibitor Response and Resistance. [PDF]

J Multidiscip Healthc
Wang X, He J, Ding G, Tang Y, Wang Q.
europepmc   +1 more source

A Case of Fulminant Immune-Related Enterocolitis During Immune Checkpoint Inhibitor Therapy for Metastatic Renal Cell Carcinoma. [PDF]

IJU Case Rep
Kanai K, Sumiyoshi T, Kitamoto H, Teramoto Y, Mine Y, Kono J, Masui K, Goto T, Saito R, Kobayashi T.   +9 more
europepmc   +1 more source

Some of the next articles are maybe not open access.

Related searches:

Immune Checkpoint Blockade

Hematology/Oncology Clinics of North America, 2014
Since the development and approval of Ipilimumab, the first immune checkpoint inhibitor licensed for the treatment of metastatic melanoma, clinicians have gained a better understanding of the mode of action, management of toxicities, and assessment of response to this class of drugs.
Jarushka, Naidoo, David B, Page, Jedd D, Wolchok   +2 more
openaire   +2 more sources

Epigenetics Meets Immune Checkpoints

Seminars in Oncology, 2015
Epigenetic alterations play a pivotal role in cancer development and progression. Pharmacologic reversion of such alterations is feasible, and second generation "epigenetic drugs" are in development and have been demonstrated to possess significant immunomodulatory properties.
Covre A., Coral S., Di Giacomo A. M., Taverna P., Azab M., Maio M.   +5 more
openaire   +3 more sources